Tarsus Pharmaceuticals, Inc. (TARS)

NMS – Real vaqt narxi. Valyuta: USD

69.72

+0.27 (0.38%)

Bozor ochiq: Aug 12, 2026, 12:51 PM EDT

70.00

+0.54 (0.78%)

Oldingi bozordan keyin: Aug 11, 2026, 7:43 PM EDT

07.08.2026

Tarsus Pharmaceuticals Q2 Earnings Call Highlights

Tarsus Pharmaceuticals NASDAQ: TARS reported second-quarter growth in sales of its Demodex blepharitis treatment XDEMVY and announced a pending acquisition of Alkeus Pharmaceuticals, adding late-stage investigational Stargardt disease therapy gildeuretinol, also known as ALK-001, to its pipeline.

06.08.2026

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript

06.08.2026

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.48 per share a year ago.

06.08.2026

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

Eye drug maker Tarsus Pharmaceuticals said on Thursday it would acquire privately held Alkeus Pharmaceuticals in a cash-and-stock deal worth up to $800 million, adding an experimental oral therapy for ‌a rare inherited retinal disorder with no approved U.S. treatment.

06.08.2026

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Generated second quarter 2026 XDEMVY ® net product sales of $173.9 million, an increase of more than 69% year-over-year

06.08.2026

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $125.0 million, before deducting placement agent fees and other private placement expenses.

06.08.2026

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of the largest inherited retinal diseases with no FDA-approved therapy

Tarsus Pharmaceuticals, Inc. (TARS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals Q2 Earnings Call Highlights

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

Tarsus Pharmaceuticals Q2 Earnings Call Highlights

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

Videolar

No Data

Press-relizlar

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

Search stocks

Tarsus Pharmaceuticals, Inc. (TARS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals Q2 Earnings Call Highlights

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

Tarsus Pharmaceuticals Q2 Earnings Call Highlights

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

Videolar

No Data

Press-relizlar

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position